News and Events

RH Nanopharmacuticals submits IND application to U.S. FDA for RHN001 AND RHN002 for Phase 1 Clinical study in healthy volunteers- May 13, 2021
RH Nanopharma strives to bring a safe and faster onset analgesic/ anti inflammatory drug with key differentiating features from NSAIDS such as
Target indications include
Develop a Safer and Fast acting Anti inflammatory agent
At RHNanopharma, we are dedicated to treating, preventing, slowing and reversing current acute and chronic inflammatory diseases.
Our current approach is to to focus on common inflammatory disease such as osteoarthritis, Acute pain, Postop pain, Traumatic brain injury(TBI), Anterior Uveitis, and Neuropathic Corneal Pain (NCP)
RH Nanopharmacuticals submits IND application to U.S. FDA for RHN001 AND RHN002 for Phase 1 Clinical study in healthy volunteers- May 13, 2021